Evidence map›Paper›PMID 26391206›Full record

ArticleJournal of bacteriology2015

The FasX Small Regulatory RNA Negatively Regulates the Expression of Two Fibronectin-Binding Proteins in Group A Streptococcus.

Jessica L Danger, Nishanth Makthal, Muthiah Kumaraswami, Paul Sumby

Open access · bronzeAbstract read
In one paragraph

Article in Journal of bacteriology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. A small RNA fromVirulence · 2025
    Article
  3. Review
  4. Regulation of biofilm formation by non-coding RNA in prokaryotes.Current research in pharmacology and drug discovery · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Streptococcus sanguinis NoncodingInfection and immunity · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jessica L DangerCenter for Molecular Medicine, Department of Microbiology & Immunology, University of Nevada, School of Medicine, Reno, Nevada, USA.
Nishanth MakthalCenter for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA.
Muthiah KumaraswamiCenter for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA.
Paul SumbyCenter for Molecular Medicine, Department of Microbiology & Immunology, University of Nevada, School of Medicine, Reno, Nevada, USA psumby@medicine.nevada.edu.
Houston Methodist · USUniversity of Nevada, Reno · US

Funding

Delineation of the molecular mechanisms underlying group A Streptococcus virulencR01AI087747 · NIAID · UNIVERSITY OF NEVADA RENO · PI SUMBY, PAUL · 2010 to 2014
$1.8M
NIAID NIH HHS R01 AI087747
6 · The paper itself

Abstract

unlabelledThe group A Streptococcus (GAS; Streptococcus pyogenes) causes more than 700 million human infections each year. The success of this pathogen can be traced in part to the extensive arsenal of virulence factors that are available for expression in temporally and spatially specific manners. To modify the expression of these virulence factors, GAS use both protein- and RNA-based regulators, with the best-characterized RNA-based regulator being the small regulatory RNA (sRNA) FasX. FasX is a 205-nucleotide sRNA that contributes to GAS virulence by enhancing the expression of the thrombolytic secreted virulence factor streptokinase and by repressing the expression of the collagen-binding cell surface pili. Here, we have expanded the FasX regulon, showing that this sRNA also negatively regulates the expression of the adhesion- and internalization-promoting, fibronectin-binding proteins PrtF1 and PrtF2. FasX posttranscriptionally regulates the expression of PrtF1/2 through a mechanism that involves base pairing to the prtF1 and prtF2 mRNAs within their 5' untranslated regions, overlapping the mRNA ribosome-binding sites. Thus, duplex formation between FasX and the prtF1 and prtF2 mRNAs blocks ribosome access, leading to an inhibition of mRNA translation. Given that FasX positively regulates the expression of the spreading factor streptokinase and negatively regulates the expression of the collagen-binding pili and of the fibronectin-binding PrtF1/2, our data are consistent with FasX functioning as a molecular switch that governs the transition of GAS between the colonization and dissemination stages of infection. IMPORTANCE: More than half a million deaths each year are a consequence of infections caused by GAS. Insights into how this pathogen regulates the production of proteins during infection may facilitate the development of novel therapeutic or preventative regimens aimed at inhibiting this activity. Here, we have expanded insight into the regulatory activity of the GAS small RNA FasX. In addition to identifying that FasX reduces the abundance of the cell surface-located fibronectin-binding proteins PrtF1/2, fibronectin is present in high abundance in human tissues, and we have determined the mechanism behind this regulation. Importantly, as FasX is the only mechanistically characterized regulatory RNA in GAS, it serves as a model RNA in this and related pathogens.

Indexed as

Gene Expression Regulation, Bacterial5' Untranslated RegionsBacterial ProteinsBase SequenceCarrier ProteinsDown-RegulationFibronectinsMolecular Sequence DataRNA, BacterialRNA, Small UntranslatedStreptococcus pyogenes5' Untranslated RegionsBacterial ProteinsCarrier ProteinsFibronectinsRNA, BacterialRNA, Small Untranslated

Identifiers

PMID26391206
PMCPMC4626899
OpenAlexW2323709439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.